NANOCRINE, INC.

Medtech · Private

A point-of-care diagnostic device combining machine vision algorithms with microchip substrates to detect viral infection through cellular phenotyping in swab samples

Grants
$249K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Rapid, pre-symptomatic detection of COVID-19 and unknown viruses using a novel biosensor chip, computer vision and machine learning.$248,706
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1305Cardiosense, Inc.—$35M
1306Forge Medical, Inc.—$180K
1307Cytrellis Biosystems, Inc.—$83M
1308NANOCRINE, INC.——
1309BRIUS Technologies, Inc.—$21M
1310POTENTIOMETRIC PROBES, LLC——
1311LASER BIOANALYTICS LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.